Phase Genomics and Element Biosciences have announced the results of their exciting first collaboration, combining Phase Genomics’ OncoTerra™ cytogenomics platform with Element’s AVITI System for next generation sequencing (NGS).
The data generated from the AVITI System showed impressive improvements in multiple sequencing metrics, making it an ideal partner for OncoTerra™ in cancer research. This collaboration marks an important step forward in advancing the field of genomics.
Phase Genomics is thrilled to extend the application of its core technologies into the oncology space with the use of its next-generation cytogenomic tools. Recent work with Element has shown incredible precision, speed and efficiency, pushing the boundaries of what’s possible. OncoTerra is NGS platform agnostic, and Element’s AVITI System is the perfect choice for data generation in next generation cytogenomics – a testament to its high quality and accuracy.
OncoTerra, powered by the Element AVITI System, is revolutionizing the landscape of solid-tumor malignancies research. Our platform enables high-resolution cytogenomic analysis of a variety of sample types, including FFPE samples, that are typically difficult to work with.
Our sequencing yields a lower level of duplicates and a higher proportion of high-quality read pairs, making it more efficient than ever before. With OncoTerra, researchers can now access genome-wide cytogenomic insights from blood, fresh, and frozen tissue samples. It’s time to experience the power of scalable cytogenomics with OncoTerra.
Element Biosciences is excited to announce its first foray into the next-generation cytogenomics space for oncology with its collaboration with Phase Genomics. Through the use of the AVITI System, this joint effort is making strides in accurately characterizing clinically relevant samples and advancing the latest technology towards the clinic. This collaboration promises to have a major impact on research in oncology and beyond.
OncoTerra is revolutionizing oncology research with its groundbreaking platform that leverages data from Element’s AVITI NGS system to identify novel and known genomic alterations. At the upcoming AACR conference, Phase Genomics and Element will share an application note that demonstrates how OncoTerra surpasses the breadth and depth of insights from current front-line cytogenetic diagnostics. Come join us at AACR to learn more about the incredible potential of this cutting-edge platform!
About Phase Genomics
At Single-Cell-Phase Genomics, we are revolutionizing the way we study genomes and metagenomes. Our proprietary proximity ligation technology enables us to assemble, deconvolute, and analyze structural genomic variation and genome architecture at the chromosome-scale.
We provide a comprehensive suite of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and humans. Moreover, our state-of-the-art genome and metagenome assembly and analysis software is driving the industry forward.
At GenoEase, we believe in the power of genomics to accelerate breakthrough discoveries. Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, our Seattle-based company is committed to providing scientists with the best genomic tools available.
With our cutting-edge technology, we strive to make the research process easier and more efficient. Unlocking the secrets of the genome is key to unlocking the mysteries of the world we live in, and we are proud to be a part of this ongoing journey.
About Element Biosciences, Inc.
Element Biosciences is revolutionizing the life science industry with their disruptive DNA sequencing technology. Their cutting-edge technology provides customers with access to high-quality data at an affordable cost, enabling them to make groundbreaking scientific discoveries and open the door to genomic medicine. By innovating every fundamental element of a sequencing system, Element is transforming the way research and diagnostics are conducted.